Loenders B, Rampart M, Herman A G
Division of Pharmacology, Faculty of Medicine, University of Antwerp (UIA), Wilrijk, Belgium.
Arch Int Pharmacodyn Ther. 1994 Sep-Oct;328(2):225-34.
The effects of the enantiomers of structurally related chiral M3 antagonists (trihexyphenidyl, p-fluorohexahydrodifenidol, hexahydrodifenidol and p-fluorohexbutinol) were studied at the presynaptic M2 and postsynaptic M3 receptor level in the rabbit trachea. All isomers were M3- over M2-selective as they did not increase the release of acetylcholine (an M2 effect) at concentrations that significantly inhibited smooth muscle contraction (an M3 effect). At the smooth muscle receptor, the R-enantiomers were consistently more potent than the S-enantiomers. The potency ratios (IC50(S)/IC50(R)) varied from 6 for p-fluorohexbutinol to 288 for trihexyphenidyl, and increased with higher eutomer potencies, in accordance to Pfeiffer's rule. Furthermore, we found that the potency of the racemic mixture of hexahydrodifenidol was significantly lower than that of the eutomer R-hexahydrodifenidol. To exclude that this difference was due to the lower concentration of the more active isomer, present in a racemic mixture, we calculated the potencies (-log IC50 values) of mixtures of the isomers of hexahydrodifenidol with varying amounts of S-hexahydrodifenidol and a constant amount of R-hexahydrodifenidol. We found that the presence of the distomer altered the potency of the eutomer in a dose-related manner. In conclusion, we have shown that the muscarinic smooth muscle receptor can be blocked differentially by the isomers of muscarinic antagonists and that the presence of the less active compound alters the potency of the most active isomer. We, therefore, suggest that, in bronchodilating therapy, the use of the pure eutomer might have advantages.
在兔气管的突触前M2和突触后M3受体水平上,研究了结构相关的手性M3拮抗剂(苯海索、对氟六氢双苯丙醇、六氢双苯丙醇和对氟己基丁醇)对映体的作用。所有异构体对M3的选择性均高于M2,因为在显著抑制平滑肌收缩(M3效应)的浓度下,它们不会增加乙酰胆碱的释放(M2效应)。在平滑肌受体上,R-对映体始终比S-对映体更有效。效价比(IC50(S)/IC50(R))从对氟己基丁醇的6变化到苯海索的288,并根据Pfeiffer规则随着优映体效力的提高而增加。此外,我们发现六氢双苯丙醇外消旋混合物的效力显著低于优映体R-六氢双苯丙醇。为排除这种差异是由于外消旋混合物中活性较高的异构体浓度较低所致,我们计算了含有不同量S-六氢双苯丙醇和恒定含量R-六氢双苯丙醇的六氢双苯丙醇异构体混合物的效力(-log IC50值)。我们发现,非优映体的存在以剂量相关的方式改变了优映体的效力。总之,我们已经表明,毒蕈碱平滑肌受体可被毒蕈碱拮抗剂的异构体差异性阻断,并且活性较低的化合物的存在会改变活性最高的异构体的效力。因此,我们建议,在支气管扩张治疗中,使用纯优映体可能具有优势。